Chemesis’ Puerto Rican Operations Bolstered by Prestigious Awards, Plus Exclusive Interview with Board Member Deepak Anand
Tony Deyes
May 5th, 2019
App, Exclusive, News, Top Story
Chemesis International Inc. (CSE: CSI, OTC: CADMF, FRA: CWAA), a Vancouver-based cannabis company with operations in California, Puerto Rico, and Colombia announced April 5th that its Puerto Rican subsidiary, Natural Ventures has been awarded Best Topical, Best Tincture, and Best Vaporizer by the FreeJuana Foundation, a non-profit dedicated to the promotion of responsible cannabis usage and education about its medical benefits.
The awards were handed out at an annual gala recognizing Puerto Rican industry leaders who demonstrate a commitment to superior patient care and developing the cannabis industry on the Caribbean island. Winners were chosen through a survey of dispensary owners, industry leaders, and certified medical cannabis patients, making them truly representative. FreeJuana is Puerto Rico’s first and largest pro-cannabis organization which hosts an annual march to draw awareness to the benefits of cannabis, in addition to bringing together experts and policymakers to help shape Puerto Rico’s cannabis regulations.
Commenting on the awards, Chemesis CEO, Edgar Montero said, “We are extremely honoured to have received such high recognition for our continued dedication to producing products that are of the highest quality. Receiving this recognition through a survey of our peers is validation that our team has developed the right approach to producing our finished goods. Chemesis will continue to employ these strategies and maintain its consistency in all areas of our business.”
Natural Ventures is a seed to sale medical cannabis company, operating in Caguas, Puerto Rico since early 2017 with 100,000 square feet of cultivation space and an additional 35,000 sq. ft. dedicated to manufacturing edibles and other cannabis-infused products. Puerto Rico legalized medical cannabis for qualifying health conditions in 2015, but only permits the sale of derivatives products. Chemesis’ wholly-owned Puerto Rican subsidiary, Chemesis PR, acquired an 80% stake in Natural Ventures last August.
Awards Raise Profile of Viverian Launch
On the heels of the award, Chemesis announced the launch of Viverian, an all-natural CBD product line, after acquiring Viverian’s CBD product catalogue in December.
Viverian is a hemp-derived CBD product line that promotes healthy living and offers quick and easy consumption methods. The line includes tinctures as well as capsules designed for sleep, relaxation, improved concentration, relief for discomfort, and improved overall health & wellness, which are lab-tested, THC free, with 100% botanical ingredients.
New regulations from the Puerto Rican Department of Health allow licensed manufacturing facilities to incorporate hemp-derived CBD in to its portfolios as long as the products are entered in to the tracking system and tested through licensed labs located in Puerto Rico. Prior to the adoption of the US Farm Bill earlier this year, hemp still carried the same legal classification as cannabis containing THC. The US was the only industrialized country with a ban on hemp, and the new regulations will enable the cultivation of industrial hemp crops. Hemp-derived CBD is the fastest-growth segment of the CBD market, and the declassification is expected to address the current shortage of CBD within the industry.
Natural Ventures anticipates Viverian products to hit dispensaries before the end of April and will also offer contract manufacturing services for other licensees in Puerto Rico.
“Natural Ventures is a key part of Chemesis’ long term strategy to build a major presence in Latin America, and by launching Viverian, it allows penetration into the Puerto Rican CBD market,” added Montero. “Chemesis believes it has an advantage in the Latin American CBD market as it is able to leverage its state-of-the-art facility, its previously announced partnership with First Medical that brings up to 6,000 acres of hemp cultivation, and its all-natural Viverian CBD product catalogue.”
Chemesis’ relationships with industry and political leaders in Puerto Rico, Colombia, as well as California, have positioned it as a strategic first-mover in all three jurisdictions, giving it an advantage over much of its competition.
For more information, keep watching this page or visit https://chemesis.com/
And connect with Chemesis in social media:
Disclaimer
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Tony Deyes
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Tom Zuber is Zuber Lawler & Del Duca’s Managing Partner. He has a degree with highest honors in biomedical engineering and has advised some of the most iconic companies in the world on their patent and trademark portfolios. He is at the cutting edge of cannabis patent and trademark law. He holds degrees from Harvard University and Columbia Law […]
Matt Hawkins is the founder and managing principal of Cresco Capital Partners, LLC (“Cresco”), a private equity firm focused specifically on investing in the legalized cannabis industry. Since its inception in the summer of 2015, Cresco has made 14 investments out of its first fund and is currently raising this fund, Fund II. Prior to the […]
Next Green Wave is a fully integrated premium seed to shelf craft cannabis producer offering products through its in-house brand portfolio and wholesale flower for other large cannabis manufacturers.
FSD Pharma is a publicly traded company on the Canadian Securities Exchange under the symbol HUGE. The Company, through its wholly-owned subsidiary FV Pharma Inc., holds an ACMPR license to cultivate cannabis under the Access to Cannabis for Medical Purposes Regulations (ACMPR). HUGE, made history on its first day of trading on the Canadian Securities […]
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
